Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
文献类型:期刊论文
作者 | Zhang,Tao1; Qu,Rong1; Chan,Shingpan2; Lai,Mengzhen1,3; Tong,Linjiang1; Feng,Fang1; Chen,Hongyu4; Song,Tingting4; Song,Peiran1; Bai,Gang1,5,6 |
刊名 | Molecular Cancer |
出版日期 | 2021-08-17 |
卷号 | 20期号:1 |
DOI | 10.1186/s12943-021-01391-x |
通讯作者 | Ding,Ke(dingke@jnu.edu.cn) ; Ding,Jian(jding@simm.ac.cn) ; Xie,Hua(hxie@simm.ac.cn) |
语种 | 英语 |
出版者 | BioMed Central |
WOS记录号 | BMC:10.1186/S12943-021-01391-X |
源URL | [http://119.78.100.183/handle/2S10ELR8/297582] |
专题 | 新药研究国家重点实验室 |
通讯作者 | Ding,Ke; Ding,Jian; Xie,Hua |
作者单位 | 1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research 2.Jinan University; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy 3.Fudan University; School of Pharmacy 4.Jiangsu Aosaikang Pharmaceutical Co.Ltd (ASK pharm) 5.University of Chinese Academy of Sciences 6.ShanghaiTech University; School of Life Science and Technology |
推荐引用方式 GB/T 7714 | Zhang,Tao,Qu,Rong,Chan,Shingpan,et al. Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance[J]. Molecular Cancer,2021,20(1). |
APA | Zhang,Tao.,Qu,Rong.,Chan,Shingpan.,Lai,Mengzhen.,Tong,Linjiang.,...&Xie,Hua.(2021).Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.Molecular Cancer,20(1). |
MLA | Zhang,Tao,et al."Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance".Molecular Cancer 20.1(2021). |
入库方式: OAI收割
来源:上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。